In what is being hailed as a groundbreaking moment in global transfusion medicine, a 38-year-old woman from Karnataka, India, has been identified as the first known carrier of a previously undocumented human blood group, now officially named CRIB. This unprecedented finding came to light when she was admitted to R.L. Jalappa Hospital in Kolar for heart surgery in 2023.

Though she was originally typed as O-positive, her blood didn’t behave like it. It reacted with every test sample available in the lab—something known as being panreactive. That raised immediate red flags among her physicians. No compatible donor could be found, even among 20 of her closest family members. Despite the risk, the surgical team completed her cardiac procedure without a transfusion—a decision that would later prove critical in her survival and in medical history.

What followed was a medical investigation that spanned continents. Her blood sample was sent to the International Blood Group Reference Laboratory (IBGRL) in Bristol, UK—one of the world’s leading institutions in blood group identification. There, a team of transfusion scientists spent 10 months conducting molecular and serological analyses to crack the case.

Also Read: James Van Der Beek Shares Health Update After Stage 3 Colorectal Cancer Diagnosis

Finally, they concluded that her blood carried an unknown antigen—a marker on red blood cells that typically determines compatibility for transfusions. The antigen didn’t match anything in the 43 existing blood group systems recognized by the International Society of Blood Transfusion (ISBT).

A new antigen was identified within the Cromer blood group system, which involves proteins called decay-accelerating factor (DAF) on red cells. To honor the origin of the discovery, scientists named the antigen CRIB, an acronym combining Cromer, India, and Bengaluru.

What Is the CRIB Blood Group?

The CRIB blood group represents a rare antigen profile within the Cromer system. In most people, antigens in this group are present on DAF proteins. But in the CRIB case, the woman lacked a high-prevalence antigen commonly found in the general population, causing her immune system to react to every available donor blood type—even O-positive.

This made the woman’s blood functionally unique. Anyone with this blood type would need extremely rare, CRIB-negative blood in the case of transfusion—currently, there’s no known matching donor worldwide.

This isn’t just a medical oddity—it has far-reaching consequences for how we approach blood donation, transfusion safety, and immunogenetics.

The CRIB blood group challenges conventional systems used for blood typing and compatibility. It underscores how standard blood typing is still incomplete, and how gaps in our understanding can be dangerous—especially in emergency surgeries or during pregnancy.

How Is This Blood Type Discovery Affect Pregnancy and Fetal Health?

The discovery of CRIB has serious implications for fetal medicine. Similar to how Rh incompatibility can lead to Hemolytic Disease of the Fetus and Newborn (HDFN), CRIB-positive mothers might develop antibodies that attack the fetus’s red blood cells—if the baby inherits incompatible antigens.

Detecting CRIB in expectant mothers could therefore become critical in preventing miscarriage or fetal complications.

India’s diverse gene pool has previously produced rare blood group discoveries, including INRA (Indian Rare Antigen), first identified in 2017. With CRIB now officially recognised by ISBT, it marks India’s second major contribution to global transfusion science in under a decade.

This elevates the importance of developing a national rare blood registry, and investing in genetic blood screening—not just for patients, but for potential donors.

What Is The Science Behind the Cromer Group?

The Cromer blood group system is one of the more obscure and less commonly tested classifications in blood science. It involves antigens located on the DAF (decay-accelerating factor), which protects blood cells from immune destruction. Variants in these antigens can cause unexpected immune reactions during transfusions.

CRIB appears to represent a novel Cromer antigen—meaning it doesn’t behave like any of the previously documented ones. This puts it in a category of what transfusion scientists call high-prevalence antigen absences, where even a single unit of compatible blood can be hard—or impossible—to find.

In an effort to find a compatible blood donor, doctors collected samples from 20 of her family members. None matched. This confirmed that the antigen pattern was not only rare—it was potentially unique.

The case was handled with meticulous care. According to Dr. Ankit Mathur from the Rotary Bangalore TTK Blood Centre, “Her blood was panreactive, incompatible with all test samples. Recognising this as a possible case of a rare or unknown blood type, we worked closely with international experts and managed the case without transfusion.” Now that CRIB has been added to the official ISBT database, transfusion scientists across the world are advocating for:

• Development of CRIB-specific antibody screening kits
• International rare blood registries to flag potential future donors
• Greater investment in genetic blood typing, especially in populations with diverse ancestry
• Training healthcare professionals to recognise and manage panreactive or atypical cases earlier

The discovery of CRIB is more than a scientific milestone—it’s a reminder of how individual cases can rewrite medical textbooks. One woman’s unusual blood has now become a catalyst for change in how we view transfusion safety, genetics, and global healthcare cooperation.

For now, she remains the only known person in the world with the CRIB blood group but her case has opened the door to more discoveries and potentially, more lives saved.

The US Centers for Disease Control and Prevention (CDC) is considering a travel advisory for China, following a sharp and unexpected outbreak of chikungunya virus, a mosquito-borne illness known for causing severe joint pain and long-term complications. With nearly 5,000 confirmed cases in China—most centered in the densely populated Guangdong Province the outbreak is drawing concern not only for its scope but also for its potential to spread far beyond Chinese borders.

For global travelers and health officials alike, the news echoes the early days of COVID-19, when regional outbreaks quickly became international crises. Now, as the WHO calls for urgent action, the spotlight returns to international coordination, vector control, and public health preparedness.

The current outbreak began on July 8, with a single imported case reported in Foshan’s Shunde district. Since then, cases have exploded Foshan alone now reports over 5,155 infections, prompting the city to elevate its public health emergency response to Level III, denoting a “relatively major” event in China’s four-tier alert system.

The spread has not been confined to Guangdong. The European Centre for Disease Prevention and Control reports that over 240,000 chikungunya cases have emerged across at least 16 countries this year, with 90 related deaths globally.

According to Diana Rojas Alvarez, medical officer at the WHO, one key factor is viral adaptation. Since 2004, chikungunya has evolved to spread more efficiently, particularly through urban-adapted mosquitoes that thrive in warm, humid cities with poor water management.

Alvarez warns that 5.6 billion people in 119 countries now live in regions at risk of chikungunya outbreaks.

That’s not just a developing-world problem. The Aedes mosquito has already been spotted in parts of the southern United States, including Florida, Texas, and Louisiana making travel-related cases a direct risk to US public health.

What Is China Doing To Curb The Outbreak?

In a blend of traditional vector control and innovative science, China has deployed extraordinary measures to curb the outbreak:

• Mass mosquito eradication programs, including spraying and habitat destruction
• Drones to detect standing water on rooftops
• Larva-eating fish released into lakes and ponds
• Public advisories encouraging residents to eliminate breeding grounds

But the most headline-grabbing strategy? Elephant mosquitoes.

First identified in Tanzania in 1952, chikungunya is not new—but its aggressive resurgence in recent years has alarmed epidemiologists. The virus is transmitted primarily through the Aedes aegypti mosquito, which also spreads dengue, Zika, and yellow fever. Infected individuals can experience:

• Sudden onset of fever
• Severe joint pain (often debilitating and long-lasting)
• Muscle aches, headaches, joint swelling
• In some cases, vomiting or rash

Though rarely fatal, chikungunya can cause long-term disability, particularly in older adults or those with preexisting conditions. There is no antiviral treatment or vaccine, making prevention and early containment vital.

These oversized insects, known scientifically as Toxorhynchites splendens, are natural predators of Aedes mosquitoes. Released by a research team at Sun Yat-sen University’s Zhongshan School of Medicine, these giant mosquitoes do not bite humans, but their larvae feast on the mosquito species responsible for spreading chikungunya.

This approach, while unconventional, highlights the urgency and scale of the threat China is facing.

Prevention Measures to Pick From COVID-19 Playbook

The outbreak has prompted Chinese authorities to revive some of the pandemic-era containment strategies that became familiar worldwide:

• Mass PCR testing
• Isolation protocols for infected individuals
• Disinfection campaigns across neighborhoods

Designated hospitals with isolation beds have been set up in affected regions, and border control checks have been reinforced in Hong Kong to prevent imported cases.

The CDC has stated that it is closely monitoring the outbreak and may issue a Level 1 or Level 2 travel health notice. These advisories typically urge travelers to take extra precautions, such as using insect repellent, wearing protective clothing, and avoiding peak mosquito hours, especially in tropical or subtropical zones.

The US currently has no reported local transmission of chikungunya, but imported cases have occurred before, particularly in travelers returning from South Asia or the Caribbean. Public health experts warn that now is the time for vigilance, not complacency.

What Travelers Need to Know?

If you're planning a trip to China or anywhere with ongoing mosquito-borne virus activity—consider these guidelines:

• Use EPA-registered insect repellent with DEET or Picaridin.
• Sleep under mosquito nets, especially in areas with poor indoor mosquito control.
• Wear long sleeves and pants to reduce skin exposure.
• Monitor local health advisories and avoid travel to outbreak hotspots, especially if pregnant or immunocompromised.

The chikungunya outbreak in China is not just a national issue, it’s a global health stress test. With memories of COVID-19 still fresh, this sudden surge is a reminder that climate change, globalization, and urbanization are combining to amplify infectious disease risks.

If the US does issue a formal travel advisory, it will mark another chapter in the growing tension between health security and international mobility.

Breast cancer survivors have lived with a guarded sense of relief. Even after beating the disease, the possibility of recurrence remains a faint shadow but new research has raised an alarming possibility- respiratory viruses, including common ones like influenza and SARS-CoV-2, may act as a catalyst, reawakening dormant breast cancer cells that linger quietly in the lungs long after remission.

In a new study published in Nature, researchers from the University of Colorado and Utrecht University have found that viral infections can reignite cancer’s flame literally. Dormant cancer cells are like the embers left in an abandoned campfire, and respiratory viruses are like a strong wind that reignites the flames.

This study marks a crucial turning point in how we understand long-term remission and highlights the importance of continued vigilance among cancer survivors.

Also Read: Legionnaires Outbreak: All That You Need To Know About The Disease That Killed 1 And Left 22 Sick In New York

Why COVID-19 Infection Is First Red Flag?

The investigation kicked off in the aftermath of the COVID-19 pandemic. Clinicians and researchers began to notice an uptick in metastatic cancer cases, especially among individuals previously in remission. Something wasn’t adding up. Cancer recurrences were occurring at an unusual rate and too often to be dismissed as coincidence.

The researchers turned to two key data sources: the UK Biobank and a large U.S. breast cancer database with over 37,000 patient records. In the UK Biobank cohort, survivors who had contracted COVID-19 exhibited a twofold increase in cancer-related mortality. In the U.S. dataset, those with prior SARS-CoV-2 infection faced a more than 40% increase in metastatic breast cancer, particularly in the lungs.

The extent of this increased risk is almost unheard of in cancer epidemiology, it’s a significant effect.

What’s Happening in the Body?

To understand the mechanics, the researchers turned to mouse models—long used as reliable proxies for studying human disease behavior. When the mice with previously dormant breast cancer cells were infected with either SARS-CoV-2 or influenza A, it took only days for those latent cells to wake up. Within two weeks, there was a more than 100-fold increase in metastatic tumor burden in the lungs.

Here’s the crucial insight, the cancer cells didn’t reawaken because the virus directly interacted with them. Instead, the viruses triggered an inflammatory immune response, rich in signaling proteins called cytokines—especially interleukin-6 (IL-6). This cytokine storm appeared to create an environment ripe for dormant cancer cells to start proliferating again.

According to lead researcher Shi Chia from the University of Colorado, “Although species differences warrant caution in interpreting mouse data… collectively, these findings underscore the substantial metastatic risk COVID-19 posed to cancer survivors.”

Role of Viruses in Cancer Biology

The link between viruses and cancer isn’t new. Human papillomavirus (HPV) has long been known to cause cervical and other cancers. The Epstein-Barr virus (EBV) has been implicated in several types of lymphoma. In fact, EBV has been found in five times higher concentrations in breast cancer tissue compared to healthy tissue.

The idea that viruses could influence cancer development or recurrence has been around since the 1930s, particularly in mouse models. But this new research is among the first to show how non-oncogenic, respiratory viruses—those not traditionally associated with cancer—might still play a key role in its resurgence.

Role of Inflammation and the Immune System

One of the most compelling parts of the study is the insight into how the immune system's response, not the virus itself, may be the real driver of cancer recurrence.

After remission, it’s common for a few cancer cells known as dormant disseminated cancer cells (DCCs), to remain hidden in tissues like the lung, bone, or liver. These DCCs are typically inactive, posing no threat unless triggered.

Inflammatory responses to infections, especially those that involve cytokines like IL-6, appear to disturb this dormancy. In simple terms, inflammation acts like a wake-up call for these sleeping cells.

The researchers demonstrated that only when the viral infections resulted in elevated levels of inflammatory markers did the dormant cells awaken. This opens up new avenues for therapeutic research focused on blocking inflammation, rather than targeting cancer cells directly.

What This Means for Breast Cancer Survivors?

This is not a reason for panic but it is a call for caution. As DeGregori explains, “If you are a cancer patient who has these dormant cells, you may end up living a normal life and dying with these dormant cells, instead of dying because those dormant cells awakened. But if you get a respiratory virus like influenza or COVID, your chance of dying from those dormant cells awakening is much greater.”

Millions of breast cancer survivors around the world, many of whom are years or even decades into remission—could unknowingly carry dormant cells. For them, a common respiratory illness may no longer be just an inconvenience; it may be a risk factor for relapse.

Could Vaccination Be Protective?

Can we reduce this risk with vaccines? It’s too early to say definitively, but the idea is promising. If viral infections act as a trigger, then preventing infection might, in turn, prevent relapse.

DeGregori’s team is now exploring whether flu and COVID-19 vaccinations could lower the likelihood of dormant cell reactivation. This would have wide-ranging implications not just for cancer survivors, but for public health policy as a whole.

The idea that a respiratory virus could reignite cancer long after remission is unsettling but not entirely surprising. As science continues to unravel the complex relationship between our immune system, viruses, and cancer, this study offers one clear message:

Remission isn’t always the end and staying healthy may mean more than avoiding recurrence it could mean avoiding infection altogether.

With 6,000 cases of Legionnaires reported annually in the United States, scientists still think it is underdiagnosed as it could be hard to distinguish from other kinds of pneumonia or respiratory issues.

As of now, New York City has fallen prey to Legionnaires' disease outbreak. At least 22 people have fallen ill, and one person has been declared dead in Harlem, as per the New York City Health Department.

The Reason Of This Spread

As per the city health officials, people became ill after breathing in bacteria sprayed from cooling tower in central Harlem. Cooling towers help regulate building temperature. The city health department also said in a news release on Wednesday that it was testing cooling towers in the area and are continuously investigating the outbreak.

What Is The Legionnaire's Disease?

As per the Centers for Disease Control and Prevention (CDC), Legionnaire's disease is a serious type of pneumonia that is caused by Legionella bacteria. This bacteria is known for causing two types of diseases, one of them being Legionnaire's disease, a severe form of pneumonia; while the other one is Pontiac fever, which is a mild illness that can include fever, muscle aches and headaches.

It is very rare that this bacteria can cause infection outside of the lungs and affect heart or wound infections, notes CDC.

Common Symptoms

Legionnaires' disease symptoms usually develop 2 to 14 days after exposure to Legionella bacteria, but it can take longer.

The symptoms of Legionnaires' disease are similar to other types of pneumonia.

Symptoms include:

• Cough
• Fever
• Headaches
• Muscle aches
• Shortness of breath

Other symptoms, such as confusion, diarrhea, or nausea can also occur.

After this outbreak, which has been linked with a cluster, the deputy commissioner of division of infectious diseases at the New York City Department of Health and Mental Hygiene, Dr Celia Quinn, said that the risk is low for most people, however, there could be additional cases linked with this cluster.

Legionnaire's Disease in the US

Cases have been steadily rising over the past two decades. While there isn’t a single known cause for this increase, experts believe several factors may be contributing, including aging water infrastructure, poor system maintenance, rising water temperatures, and improved disease tracking and awareness.

Outbreaks are more common during the warmer months, particularly summer, when more buildings rely on cooling towers for air conditioning systems.

Health professionals note that while a similar report in winter might raise fewer concerns, the combination of summer heat and rising case numbers highlights the importance of staying vigilant during peak Legionella season.

Who Are At Risk?

While most healthy people exposed to the bacteria do not get sick, people who are 50 or older, or are current or former smokers, or people with a weakened immune system or chronic conditions, such as cancer, lung disease, diabetes or kidney and liver failure may be at a higher risk.

Legionnaires’ disease often becomes more severe within the first week of symptoms. In serious cases, patients may need hospitalization and oxygen support. If the illness progresses, it can lead to complications like lung failure or heart damage. According to the CDC, about 1 in 10 people who contract Legionnaires’ disease do not survive.

Is It Contagious?

Legionnaires’ disease doesn’t spread from person to person. It’s usually contracted by breathing in mist or vapor contaminated with the bacteria. Outbreaks are often linked to cooling towers in large cities. In rare instances, the illness can also be caused by inhaling contaminated soil.